John Haurum

John Haurum has a long and successful career in the international biotech industry. John was previously Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer. Under his leadership, F-star successfully raised €200 million in equity and non-dilutive funding. John also led the formation of several strategic collaborations with leading pharmaceutical and biotechnology companies in immune-oncology, including AbbVie and Merck KGaA, and in central nervous system disorders with Denali Therapeutics. John was also instrumental in the development of the next wave of immunotherapies, establishing a substantial pipeline of candidates with the potential to benefit cancer patients. Prior to F-star, John was VP Research at ImClone Systems, prior to this he was the CSO and Co-Founder of Symphogen.

John is currently Executive Chairman of the Board at Synklino. Dr Haurum has a Medical Degree and MSc in Immunology from Aarhus University, and a DPhil in Immunology from the University of Oxford.